Pembrolizumab (MK-3475)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Feb 25, 2019 → Feb 15, 2024
NCT ID
NCT03783078About Pembrolizumab (MK-3475)
Pembrolizumab (MK-3475) is a phase 3 stage product being developed by Merck for Merkel Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03783078. Target conditions include Merkel Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03783078 | Phase 3 | Completed |
| NCT02736266 | Phase 2 | Completed |
Competing Products
20 competing products in Merkel Cell Carcinoma